Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLIFree Report) in a research note issued to investors on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

BCLI stock opened at $0.38 on Thursday. Brainstorm Cell Therapeutics has a 52 week low of $0.13 and a 52 week high of $3.46. The firm’s fifty day moving average is $0.29 and its 200 day moving average is $0.62. The firm has a market cap of $18.37 million, a P/E ratio of -0.85 and a beta of 0.22.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Free Report) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.14). During the same quarter in the prior year, the business posted ($0.19) earnings per share. As a group, analysts forecast that Brainstorm Cell Therapeutics will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A number of large investors have recently added to or reduced their stakes in BCLI. JPMorgan Chase & Co. grew its holdings in Brainstorm Cell Therapeutics by 27.5% in the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock worth $827,000 after acquiring an additional 53,036 shares during the last quarter. State Street Corp boosted its stake in shares of Brainstorm Cell Therapeutics by 10.8% during the 1st quarter. State Street Corp now owns 96,060 shares of the biotechnology company’s stock valued at $323,000 after purchasing an additional 9,357 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Brainstorm Cell Therapeutics during the 2nd quarter valued at about $47,000. Virtu Financial LLC bought a new stake in shares of Brainstorm Cell Therapeutics during the 2nd quarter valued at about $57,000. Finally, Jane Street Group LLC bought a new stake in shares of Brainstorm Cell Therapeutics during the 2nd quarter valued at about $33,000. Institutional investors own 20.97% of the company’s stock.

Brainstorm Cell Therapeutics Company Profile

(Get Free Report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Read More

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.